123-i

Adam I-123 is a radiopharmaceutical containing the serotonin transporter (SERT) ligand, with SERT-binding and radioisotope activities. SERT is a monoamine transporter protein found in the membranes of neurons and platelets.

Iobenguane I 123 is a bioactive chemical.

Iofolastat I 123 is a diagnostic agent under investigation in clinical trial NCT00992745 (A Phase I Pilot Study in Subjects With Metastatic Prostate Cancer).

MIP-1095 I-123, as a radiotracer, is under investigation in clinical trial NCT00712829 (Evaluating the Safety, Pharmacokinetics, Tissue Distribution, Metabolism and Dosimetry of Two Prostate Cancer Imaging Agents).

AAK1-IN-1 (example 123) is an AAK1 (adaptor associated kinase 1) inhibitor with an IC50 of 2.2 nM. AAK1-IN-1 can be used for neurodegenerative diseases research[1]. Adaptor associated kinase 1 (AAK1) is a member of the Arkl/Prkl family of serine/threonine kinases. AAKl mRNA exists in two splice forms termed short and long. The long form predominates and is highly expressed in brain and heart. AAKl is enriched in synaptosomal preparations and is co-localized with endocytic structures in cultured cells. AAKl modulates clatherin coated endocytosis, a process that is important in synaptic vesicle recycling and receptor-mediated endocytosis[1]. [1]. Guanglin Luo, et al. Biaryl kinase inhibitors. WO2015153720A1.

Selisistat (EX-527) is a potent and specific inhibitor of the deacetylase SIRT1 (IC50 = 38 nM) and can be utilized in the study of neurological disorders such as Huntington's chorea.

KDM4-IN-2 is a potent and selective KDM4/KDM5 dual inhibitor with Kis of 4 and 7 nM for KDM4A and KDM5B, respectively.

N-[(1S)-5-tert-butyl-2,3-dihydro-1H-inden-1-yl]-N'-1H-indazol-4-ylurea is a potent TRPV1 antagonist, blocking activation of TRPV1 by capsaicin with the IC50 of 123 nM.

Acitemate(Chinoin 123) has an inhibitory effect on atherosclerosis and reduces the permeability of the aorta in rabbits fed a hyperlipidemic diet, which can be used to study atherosclerosis.

Compound Fr13616, with CAS No. 123-00-2, is a fragment molecule that serves as an important scaffold for molecular linking, expansion, and modification. Compound Fr13616 provides a structural basis and research tool for the design and screening of novel drug candidates, and is commonly used in drug discovery, drug synthesis, and related research.

Compound PDK0050, with CAS No. 123-56-8, is a fragment molecule that serves as an important scaffold for molecular linking, expansion, and modification. Compound PDK0050 provides a structural basis and research tool for the design and screening of novel drug candidates, and is commonly used in drug discovery, drug synthesis, and related research.

DHFR-IN-4 is a potent dihydrofolate reductase (DHFR) inhibitor with anti-tumor activity, which also inhibits EGFR and HER2, and is useful for studying pancreatic cancer.

LSD1-IN-6 increases dimethylated Lys4 of histone H3, shows no effect on expression of LSD1. LSD1-IN-6 is a potent and reversible inhibitor of lysine-specific demethylase 1 (LSD1), with an IC50 of 123 nM.

Rotigaptide is a novel and specific modulator of Cx43 and is a potent AAP. Rotigaptide prevents the uncoupling of Cx43-mediated gap junction communication and normalizes cell-to-cell communication during acute metabolic stress.

SILA-123, an inhibitor of FLT3 (FLT3-WT: IC50=2.1 nM; FLT3-ITD: IC50=1.0 nM), induces cell apoptosis by hindering the cell cycle progression at the G0 G1 phase through the suppression of FLT3 phosphorylation and its downstream signaling pathways. This compound is utilized in the study of acute myeloid leukemia.

Antifungalagent 123 (Compound 4b) demonstrates strong affinity for the oxidoreductase of Staphylococcus aureus or membrane proteins of Candida albicans, exhibiting both antibacterial and antifungal properties. Additionally, it is capable of scavenging free radicals, showcasing antioxidant effects. Antifungalagent 123 also inhibits the TLR signaling pathway and possesses anti-inflammatory activity.

Tyrphostin 63 (compound 13) is an epidermal growth factor receptor (EGFR) inhibitor, with an IC50 of 375 μM and a Ki of 123 μM.

PROTAC CG167 is a potent and selective PROTAC degrader of CypA. It degrades CypA in a dose-dependent manner in Jurkat cells, with a DC50 of 123 nM. Additionally, PROTAC CG167 exhibits antiviral activity by inhibiting HIV-1 and HCV. (Pink: CypA Ligand; Black: Linker; Blue: E3LigaseLigand)

RH01201 is a non-competitive inhibitor of plasmepsin II, with a Ki of 123 μM.

Fluindione is a hematologic drug.

Antitumor agent-123 (Compound 4d) effectively inhibits various kinase targets with anticancer properties, including JAK2, JAK3, HDAC1, and HDAC6, with IC50 values of 34.6 μM for JAK2 and 2.6 μM for JAK3. In solid tumor models, Antitumor agent-123 demonstrates moderate activity.

P-gp inhibitor 18 (compound 6G) effectively inhibits P-gp, reducing the efflux of Rhodamine 123 in P-gp overexpressing leukemia cells, such as K562/Dox.

P-gp inhibitor 19 (Compound 6i) is a P-gp inhibitor that blocks the efflux of rhodamine 123 from P-gp overexpressing leukemia cells K562/Dox and restores the sensitivity of DOX-resistant cells.

SC-514 (GK 01140) is a selective, orally active, ATP-competitive IKK-2 inhibitor (IC50=11.2±4.7 μM), obstructs NF-κB-dependent gene expression.